<SEC-DOCUMENT>0001193125-11-103691.txt : 20110420
<SEC-HEADER>0001193125-11-103691.hdr.sgml : 20110420
<ACCEPTANCE-DATETIME>20110420161414
ACCESSION NUMBER:		0001193125-11-103691
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110414
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110420
DATE AS OF CHANGE:		20110420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		11770778

	BUSINESS ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): April&nbsp;14, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>CERUS CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>68-0262011</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File No.)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2550 Stanwell Drive
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Concord, California 94520 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (925)&nbsp;288-6000 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Resignation of Claes Glassell </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;14, 2011, Claes Glassell informed the Board of Directors (the &#147;Board&#148;) of Cerus Corporation (the
&#147;Company&#148;) that he was resigning as the Company&#146;s President and Chief Executive Officer and as a member of the Board, effective as of April&nbsp;18, 2011. This decision was not the result of a disagreement with the Company on any
matter relating to the Company&#146;s operations, policies or practices. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Appointment of William M. Greenman as President and Chief
Executive Officer and as a member of the Board </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;18, 2011, the Board appointed William M. Greenman, the
Company&#146;s current Senior Vice President, Business Development&nbsp;&amp; Marketing and Chief Business Officer, as the Company&#146;s President and Chief Executive Officer, effective immediately. In addition, the Board elected Mr.&nbsp;Greenman
to the Board, effective immediately, to serve until the next annual meeting of the Company&#146;s stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">William M.
Greenman, 44, served as the Company&#146;s Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named the Company&#146;s Chief Business Officer in April 2010. Previously, Mr.&nbsp;Greenman served as
President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006, Mr.&nbsp;Greenman served as Vice President, Business Development after returning to the Company from a brief time in the venture capital business. Prior to joining the Company
in 1995 as Director of Business Development, Mr.&nbsp;Greenman worked in various marketing and business development positions in Baxter&#146;s Biotech Division from 1991 to 1995. Mr.&nbsp;Greenman has served on the board of directors of Aduro
BioTech, a venture backed private cancer vaccines company, since June 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with Mr.&nbsp;Greenman&#146;s
appointment as President and Chief Executive Officer, the Board approved following changes to Mr.&nbsp;Greenman&#146;s compensation, effective immediately: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in Mr.&nbsp;Greenman&#146;s annual base salary from $321,360 per year to $415,000 per year; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the grant of an option to purchase 550,000 shares of the Company&#146;s Common Stock at an exercise price of $2.72 per share, which shall vest as to (1/8th)&nbsp;of the
shares six months after the date of grant and 1/48th of the shares vest each month thereafter ; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">an adjustment to Mr.&nbsp;Greenman&#146;s target bonus percentage under the Bonus Plan for Senior Management of Cerus Corporation from 35% to 60%.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Greenman will not receive any compensation in connection with his service as a member of the Board.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the Company&#146;s press release, entitled &#147;Cerus Appoints William
&#147;Obi&#148; Greenman as President and Chief Executive Officer&#148; is furnished as Exhibit 99.1 hereto. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial
Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated April&nbsp;20, 2011, entitled &#147;Cerus Appoints William &#147;Obi&#148; Greenman as President and Chief Executive Officer.&#148;</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERUS CORPORATION</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April 20, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin D. Green</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin D. Green</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance and Chief Accounting Officer</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated April&nbsp;20, 2011, entitled &#147;Cerus Appoints William &#147;Obi&#148; Greenman as President and Chief Executive Officer.&#148;</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g177617g56s15.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cerus Appoints William &#147;Obi&#148; Greenman as President and Chief Executive Officer </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONCORD, Calif.&#151;(BUSINESS WIRE) &#151;April 20, 2011&#151; The Board of Directors of Cerus Corporation (NASDAQ:CERS) announced today that William
&#147;Obi&#148; Greenman has been appointed president and chief executive officer, and a director on Cerus&#146; Board, effective immediately. Mr.&nbsp;Greenman succeeds Claes Glassell, who has resigned as president and chief executive officer, and
as director on Cerus&#146; Board, to join a privately held company. Mr.&nbsp;Greenman previously served as the company&#146;s chief business officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are extremely fortunate to transfer Cerus&#146; leadership to Obi, who has already applied his passion and depth of knowledge to critical roles at the company,&#148; said B.J. Cassin, chairman of
the Cerus Board. &#147;I believe he is the ideal person to drive the company forward to grow sales in Europe and pursue new opportunities for the INTERCEPT platelet and plasma systems in Asia, South America, the United States, and beyond. Obi&#146;s
INTERCEPT development experience will be particularly valuable as the company seeks to advance its red cell system through Phase III trials toward commercial launch.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;I&#146;m excited by the opportunity to build on the success Cerus has achieved to date,&#148; said Mr.&nbsp;Greenman. &#147;I am deeply committed to Cerus&#146; mission to protect patients from
transfusion-transmitted infections. I believe our INTERCEPT Blood System will have a global impact on blood safety, and look forward to leading the company into this next phase of growth. I plan to share my vision for Cerus at our upcoming earnings
call on April&nbsp;28.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Cassin also stated, &#147;We greatly appreciate Claes&#146; strong and effective leadership during his
service as CEO. His contributions have been instrumental in growing sales of the INTERCEPT Blood System and bringing improved blood safety to over 80 blood centers in 15 countries. Claes and Obi have worked closely together, and we expect this
transition to be seamless for our customers, distribution partners and employees.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Greenman&nbsp;has been Cerus&#146; chief
business officer since April 2010. Previously, he was senior vice president, business development and marketing. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, he served as vice president, business
development. Prior to joining Cerus in 1995 as director of business development, Mr.&nbsp;Greenman worked in various marketing and business development positions in Baxter&#146;s Biotech Division from 1991 to 1995. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ABOUT CERUS </B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Cerus Corporation
is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such
as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in
other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-right:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press release contains forward-looking statements. Any statements contained in this
press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to Cerus&#146; expectations regarding the transition in leadership and the impact of the
INTERCEPT Blood System on blood safety. These forward-looking statements are based upon the company&#146;s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including,
without limitation, risks associated with our ability to effect a smooth management transition, the success of clinical trials, sufficiency of capital resources and commercial adoption of INTERCEPT pathogen inactivation technology, as well as other
risks detailed in the Cerus&#146; filings with, the Securities and Exchange Commission (SEC), including in Cerus&#146; annual report on Form 10-K for the year ended December&nbsp;31, 2010, filed with the SEC on March&nbsp;16, 2011. You are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events,
changed assumptions or otherwise. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lainie Corten </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Global Communications&nbsp;&amp; Marketing </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cerus Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(925) 288-6319 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g177617g56s15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g177617g56s15.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)@"2`P$1``(1`0,1`?_$`+L```(!!`,!````````
M``````D*!P`"!0@#!@L$`0`"`@(#`0```````````````0(#!`D&!P@%$```
M!@(`!`(%!0H)#0`````!`@,$!08'"``1$@DA$S$4%18*(C(C-1=!8C1DU%56
M-U<Y,Y75-I:7&#A846&!H4-CI&5G=[?7*!$``0,"!`('!`@&`P```````0`"
M`Q$$$@4&!R$Q05$B,A,6"&'2%!5Q,Y/35)15E?"!HE875Y&A(__:``P#`0`"
M$0,1`#\`;-[FG<UP]VU<01EPN,;(Y#RSD*2]U<'X/JRB1[ADNXN.E)JV02^D
M4CX)JX5)ZT\,02EY@F0#*&`.!38PO-.A#ZQWIIW9][8-KE+=S=FSZ<5&Y,4)
M*'U-U2@H)DZ@(!_R>-(?)=^L;20DG\^V2.0QQ:B11(X="@`8H@`I%S&\&BOM
M*[1.?#Y8G4:D>TS=3>*FW8AUG07`V726,WM%<AS&?>P92-)%]7K1Q5$GS!^;
MX!P(\4]("')?L?\`>D[:>XFE]#>;PVW:'3[8#9/&>%6TU<(6O!.5\D_/)-R5
M"V,_9A#0SB:B$5!1?-EU&QC_`$8<E.$I#`YIX4<`CM;46[;V&S>JPP<WN[^J
M!6(%8K.)A6DE#!)J*O2.Q`[A$OTY_H^L/,Y!X>CCP!Z@M2>I/+-UW6FU#,UF
MT[\!;N#(8&2P>*3('\7#O'LXABZN2]H;(Y#L'F&VS;K<IV6Q9Y\;,,<LSHYO
M#`86\&GD.UA[/6H4]_.YC^B5U_HK!_E7'5GF_P!=OZ;FOY2W]Y=C>5_1O^/R
M[\U-[JKW\[F/Z)77^BL'^5<'F_UV_IN:_E+?WD>5_1O^/R[\U-[JD/`]SW:D
M<]8^CLOL[W%TIR[F"SC9W`LH^%531K<HJU!ZLW25Z2`_!$Q1!0O-3I]/HXYG
MM%JCU4WV[^366Y,6;V^EI)9O':^WCC@(%M*68W-!X>)@([0JZGT+BFYVG?3C
M9[7YK=Z!DRN?43(XO!<V=[Y@3<1AV`.(XX,8/9-&U69SOI#NYEW.=WO]$[GV
M8->L4S2<26I8DQYB_&U@;UM1E&-&D@=2:MS%TY<!)/DU7!@Y#TB<`#D'/C9`
MO"`<T"E.*#MOKEWO3]G2/@]B$=C*QOOJ8UL+&*R`RRAC:)JV0*P$BN'J0V"3
MIX()Q<-)N1%NG(,R'*V/T$5+](412FT1OX4HY,`Z+;GXR[C>IM3V$Q0ZEZVP
MO$7*UZQ1!7*);-CJ\L$!C[)!"[!-1`9.OOU>INX`ADU``B@`("(<-5N:6.H4
MJAWJ-K^X?VZ-O\'X.P?O5E^5Q_G^K0KI`;_#4VPS]-=N[TPISY9A,A`,PDC"
M5\5<AE"<RB42"'(>?`KHVM>*D<0G'-><:63%V-H:#M^7LAYKL;MJRDI:Z9&>
M1J\HY?.&2`N4X]K$QT:SC(L5^HZ:`%.)`-RZAY<"H/-3:X2%PW70!59`5D54
M@7;F`BZ(J$,3S4#B4P$63ZN91$!Y&`/#@22?O=FRAOMICN[HUK_@G?K,Z6/=
MU+`O3Y!*]Q5,M,WCQW%7BD0+V5AIH*^T5D`?LKD02D5)S2,W,'B!^8"O8&N8
M21Q"+[W"M]JUV<M,8NWW.QWC9#+5@F%J;BICD"59^W[_`'EZT<2)G%FDX>/C
MT(JIP39N95P*"/F`3H13YJ*%$!5M:9'=06L>N>F_<FW5QC4=A-S>X;EK""^5
MH&+N]=USU:AJE2:G1JS8XPKZOL+%/RD5+S<G948EXF+@"*^64YS`?FIU=*'M
M4BYK31H42;C]LWN,ZV86O6:](.Z?L_+SF)Z7.VQQA[*X5"PQEGK-6C%IN7B8
M&91KXOC3ZK5@<[9%P42+J%!(#%,8.;3#V$T<`IA^WK<W]M,C^YG^V+^;Z/\`
M>8_:%^`?6GXG\S[S@4:-]O>0HM4;<EW4_B0\EY9NH>]N&-,:Y8!Q%7W0@ZA8
M@:JX;5ZHS96IO-:$<O+<Y>/G!?E%5<D(;P$O"5CNQ%3I*=^X:QU7`A0AG3!5
M9SU%XYC+*\>1X8SS;B/.4$Z8)H'<&L>(+I&7.(8*&7`?*8RJ\=ZLY$G(_JZI
MP#Q'@3!(Y*;0.43"0#%$Y0`QB`(=0`//D(EY\P`>7APL3<6&HQ#HZ4874Q4.
M$]*NX:2K@0K1,4HE*8Q0$XB!0$0`3"`<Q`H#XF$`#[G"+F@@$@$\O:F&N()`
M-!S5W#20\^[)#5"?[;.Z,7>U$TJRM@:YKO%%4".2`]CVJ<A!\T5#$*833S5L
M`#SYE$0,'B`<!4F=\4YU07OA'*O8HKM\Y-M$J1P2%N.?9U:N"J*_DG+!0<7$
M3!FQ5?HNCVFF8#"F'(3<^?CP*R?OK0WXIQL@Z[AG:X;+IE41=MF[1R7T"JW6
MV!QRDHD8P<C=(IJF#T^'4/+A%2A[I_CH3S:**3=%)NB0$T4$R(I)EY])$DB@
M1,@<^8\BE*`<-8ZY.!"4(^(-_>E=C?\`[N6;_P`IX,X1Y*^+ZMRD;XKK4[)F
M:M2\3Y[QQ%RMA0UJNDS)WZ&B@<.EV%(N#!HR<VXD8@107@5Z9C&8+&`!,@V<
M**?,*<>&E"0'4/2LYV1>_I@+8S%V*M5]D;)$8@V1I59KF/ZW+6)XA'TO-+6!
MCT8>(?P4VL*3*-M[B/:)"[8.#)><OUJ("8H](*J)(B"2.2:/43;O&YTE2(NF
MCI$R:B:A2+MW+=<@E.0Y#`9)9%9(W(0'F4Q1_P`G#5*Q/NQ6_P!'H/ZK]B?5
M+#ZE_-'X/]5_B_\`!?>\"$@I\,!,,J;W5-R*+8>J*LUFH-[:Q,4Y`$7*J]<R
MHYF)5/RC<C=3>/=D4$`#P`W/A+)E[@*]`?AK&5<"%7`A"RVMUZV7R5FQ>RXI
M>R<55S5>%CS/6M]4K*1G[4[]1PD#!"3:KJ<O,)S/T"41'T\:_/4/LQOKKK=1
M^>[>2SV^0?+X(_$9F!M1XC#(7#PVRL<>8J:4]J]M;';K[.:/VX;D^N(X9\[^
M-F?@=8BX.!P8&G&Z-S1R/"M5%*.I.\IDDS'RR\0,)"B9$V0990R0\OF&.1P8
MAQ+Z.8"(#QU]%Z<O5BZ-KG:CD8ZG=.83$CV5#B#_`"7-Y-]_32)"&Y%&X5YB
MQB%?;0M!'_"O-J1O(!3"&7'9Q`!$"A?Y<!,(!X%`3+@4!'_/X<3=Z<?5B&DM
MU)(33E\PFX^SO*(WW]-1(!R&,#K^!BX?TKM6`M:MK:/G?'UMR/)RLU3XMY,*
MS+E?(JLZ@W%W7YIFWZXAQ*KJ*E%XNGXE3$I1,`^'+C[NSVQ?J'TIN[DVH];S
MW%UIJWEF,SG9D;AK<=O.QM872N)&-S>(;0$@]"^+NEO#L=J3;'-<ATC#!;9_
M/'$(FML!"789XG.I*V)H!P!W-U2`>M;>;P[*V_4/7:Z;"U;"5HS\RQNDG-W.
MB4>3C8^WHTQ(JGMFRPR,J8C:5+7R]"SEN4?-!KYBI0$J9N6R1>#&@.-#P2V#
M7<_.'Q*-*NFI^ND)7]1]98J4J#G:.ZWJ\P=GSA9JDH\+)HTZAXZKYS^7"S#I
MB`FEG"@-/6&_D'.F8HE.E9A$1J[B>A-'ZQZVXJU&P9CS7K"T$$!CW&T"VA(=
MNH8JS]\HF0!>S,P[*1,7\U+NA,NY7,'-14XCZ.0<-5$EQJ4FW\4XNDU[A?:V
M=+G!-!L@W<KJ#X@FBAL#C=54X\O'D1,@C_HX15\/=*>:25372371.51)9,BJ
M2A1YE.FH4#D.4?NE,40$.&L=<G`A*&_$#H+.>ZAV,F[=)1==;+]E3112()U5
M5#94P8!2)D*`F.<P^@`X#R5\7U;DW/(1["68/8N49-)*,DFCEA(QT@V1>,'[
M%XB=N[9/6;@BC=TT=-U#$434*8AR&$I@$!$.!4)-?NK_``O%?OKRT9\[=;AA
M2;DX6=V*P:XS3P&=1GI$RJCI=7%LZL8A*C)++&`Y&#HX,NL#"DJ0PD2!*]DU
M.#D-[MD]]S:[MPY9;:A]PJ/R!:L-UR<0ITVCD1O)&S'@`Q%_5!>-7$@F>4MU
M18J#YBK)P95P"'6=LL;D1(12?&'BK>:?8_M2:]?M>H_ZG?[0'UZS_4W^T'^$
M_F]_OO\`5PUCT/4D1NY_CO*W9;[S].W_`,<UIXYP;EZ[&O4<9@@JWA7R<^R1
MC,QXC<+H&!!H]49)F>LD#*`9<G0<0`O,.%R60RDD>$\T]_K9LCA_;3#5+SO@
MVWQURQ]>(I"1CG[)9,[J.=&3(+Z"FVA#F5BYV(<"*+ILIR.FH4?240$6L<@@
MT/-3MP)*!MBM@ZCK918B\V]E)RJ-AR%C[&,!#0PL_:LO;,DVB/JE=8,B/7#9
M%0QW\@4YPZN8)$,8`'EP)@54GO[S3(J6&"D[57XZ:!)%<8M]+L6K\$''7Y"H
MMEUR*@FMY9ND>7(>0\<?O-6:8R_,3E-_F%E#F@:UWA/FC9)A=7"<+G`T-#0T
MXT*^U:Z:U#?6/S.RL;N7+BXM\1D3W,Q-IB&(`BHJ*BO"H7+[Z4_]*J[_`!U'
M?E/$_-&FOU"R^WC]Y1\NY_\`@;O[&3W57OI3_P!*J[_'4=^4\'FC37ZA9?;Q
M^\CR[G_X&[^QD]U?.C?J0YE6D$VMU<<33\QR,HI"9CUG[LR:!W)RMVJ:YEE1
M(W2,<>0#R*41]`<4Q:PTI/F,>409E8OS28D,B;/&9'D-+B&L#BXT:"XT'($J
MR32^I(;&3,YK"\9ET0!?(Z)X8T$AHQ.+0!5Q`XGF0%V9TU:OFKEB^;(/&3Q!
M9J[:.D4W#5TU<)F1<-G+=8ITET%TCB4Y#`)3%$0$!`>.1KX21&[G&E&=.Q[N
M)!=T3M_,%DM=;%82HY5QFW%8\#3G5B>@K/T2>9I>>LIB^Z"D*C%YT"I#/NDO
M,0`IE$LACA(W`_FFW>W[O[@KN*8`KV<<+3:`KJ-V;'(-"=ND36C&EQ%HFM(U
MFPM"B50`24$PM792^0]0Y*)B(<P*U2YI::%++?%SX;L\>EI?M]`QCF08XNM$
MQ09IR@D<Z,0X>RL3>*TJ^4Y'102E)B`]63,8OBJ(!]WEPE;`>837.GN=ZELS
MJ_@O.=)FFL]!9$QI59H7S0Y#E)+#%-FT^P6*GR!)S'3:#A!0@@40,3T`'+AJ
MEP(-#S6R?`DE,]O!#>'XC_2/#=$%.Q5SM^TU3,N6)N/6%S'4ZRGEVEQ1A98[
M980;2AY"$@&W08"CYL@D4P"`#TG2KF]F(D]*90B=BZ'+[+W/5=$'R62:5B*G
M9I?>;ZH$>\I]RL]DJ;,[+I<B],Y8RM;."_4D5,`63Z3"/,`%53A7H4^<"24)
M^+;UIPN^U9Q9M6I%PL%G*LY;K^,4+"V29LY6[TVSP%B?NH&8.0J;J9/7UZ\D
MNR.<3BT2.L4/DG#DBKH2:TZ$L_\`9'N=^9+=^YV]YOP.6_NO?FGYGX/^+?-^
M]X%=P_J_[7HK]S!KH<^U/O3+N+25,AM=G0(-Y"6M2<@K*QD^MUIQ#ZAIP#"5
MMJEU:JF$[0(ELX=CR'Z,Z?646L5F+%V>:3]TBUYV"QOE*^W'X?/N`&V+P^E(
MD>VW$F:<&;#8\IQG)U1,S@K'8<DXGK&'Y>;;M^13/&\Q#2ZJ7CY9"<+Z%>X@
MBD@H?Y(\M>VJ^(IC808^U=K'7.T6-(AD36.!VTQC6(9VL3J(#Q"O/[O./4&Z
MQ@`Y4CO.L"CR$0'T-5X8NLK2V>BNY5EG?+0;(O=JL^)-5\'UW8BN.L#Z^XO9
M7C(S&^Y[35.?'439+ICB)R)1F,ZXD.1"NK).P[`B'4*"7F>D4NR&G!Q14MWJ
M)BRQ9]4?7?.,1CQX-3KJ(PJU)OUCD2MB+2')YZQ`5Y[%"18IAZ">L=8"7Y0%
M`0YZO_59I';_`#O>%UWJK5EMDMS\MMF^`ZQS"YDPATG;Q6]N^&CJFC?$Q5':
M`J"M@WINU-K;*=KA;:;TU<9M;_'3GQA>6-O'B(C[&&>=DM105/ATX\">*U7^
MR+6/_%NC_4WD_P#D3CSY_C?8?_8[/V7-?N%W=Y]WF_L-W[MEWWRK[(M8_P#%
MNC_4WD_^1.#_`!OL/_L=G[+FOW"//N\W]AN_=LN^^4YZKX[P]![&XVD:9L%#
MWB0;/9P6E?-0,BU^0DO,JTRDH5!W+5Q*'0,@FH=4?.<I@)4Q`HB80*/;/I]T
M7MGE.]N17NF-9VV;7L<L^"W^7YE;R2UM)@0U\UL(6EH)<<<C00V@)<0%UIO;
MJS7^9[1YQ::ATI<9;:OCAQ3_`!UA/''2YB();%<&5U2`T8(W$%U31H)1T>-M
M2UGJ+,W_`&0_9#D?[??='[%O=":^TWW\]4]T/=#U-3VO[<]=^@]5]7Y\O]IY
MG3Y?TG3P)BM>'-(M:QX.JM2WEE<G?#G[K,,KI'\^1RQK1E?$VQ]8H#2H^T%1
M-7IC)=FQ1`XZEZHJN8P12[V4CY-NH!?5%7/RA,OH602<-)0F3<_9;D<@ZFY2
MK7=^U&J6OFM+^H.&V6LB,,ZTC*%7A%P$B<3(U*,K*1LH+6=27\M2*)&Q#N03
M6Y`!#\C`9JH=X>&>T@I]M##FYN$F5XMO91V]Q]NEI.\M3THXIVAQ1G_#+2'E
M55!6<%I%GO\`0J17GT^U3`$7[J(?B@H<2G<L@,)>DXJ;BT_6"CO8BT7"8[_.
M;JVO6$J;J'I)#O8PZ%JR9'6>S[`Y*AVA"F+(/\=U:KQ[Z-5L*Z8];1%P@Z`!
M#IZ@.)3`*'_F.LK.]EBB]N_',7GNJZIYOG]AMFV-O*;<7*66J=D:@9TGKXH\
M?BK[?J.5ZQ5K-"UY&3!8"HM4G#8%Q+YRZBGE"`A^(TKP;T+1'NA89SS:>\'B
MC(>@^X-8QKN]$ZN5=DYU^L^+,VS$39L11][O[OVY9+_4\;VW%*=7L$N\6:+,
MYV1C!;K,TU"J%450'@Z5)A'AT<.S5;UT_,OQ`+2,/`7/332Z<L"+%+IR%&9]
M>UVL.GO-,JABU`!L4Z0>1Q,)17(3Y`\C#S*'`HTBZRAB[A82K$GGK!65/B)-
MT:G7J427.K@O5G`.'-@E=:U)\KAD9VE>,ML*!/QAY/R01+(I/GB*BJ0F$CE%
EL`@9?2IM/`B(<>M-0_\`S[_TU_4W_P`E_45_Z_\`^$X:IXK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
